ClinicalTrials.gg
CompletedNCT06193148Updated Dec 12, 2024

A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants

A Phase 1 interventional study of Jaktinib and Placebo in Healthy Participants, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate the effect of Jaktinib Hydrochloride Tablets on QT/QTc interval in healthy subjects after a single oral administration.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd is the lead sponsor of 83 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily sign , able to comply with the requirements of the study.
  • Age 18-45 years old, both male and female;
  • Weight: male ≥ 50 kg, female ≥ 45 kg, 19 kg/m\^2 ≤ ≤26 kg/m\^2.
  • 12-lead (ECG) examination, 300 ms≤\<450 ms, 120 ms≤PR interval ≤200 ms, and QRS duration \<120 ms;
  • The subjects (including male subjects) are willing to voluntarily take effective measures within the next 3 months.

Exclusion criteria

Exclusion Criteria:

  • Have a history of risk factors for torsade de pointes, or have a family history of short syndrome, long QT syndrome, unexplained sudden death in young adulthood (≤40 years old), drowning or sudden infant death syndrome in first-degree relatives;
  • Previous history of hyperkalemia, hypokalemia, hypermagnesemia, hypomagnesemia, hypercalcemia or hypocalcemia;
  • Subjects who had donated blood or lost ≥400 mL of blood within 3 months before screening;
  • , antibody, antibody, or TP antibody antibody positive.
  • Women with positive blood pregnancy test (applicable to women) or lactating women;
  • Subjects who have other factors that the investigator considers unsuitable for participation in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Jaktinib 100mg

    6 Participants will receive Jaktinib 100 mg, orally; 2 Participants will receive placebo, orally.

    Drug: Jaktinib · Drug: Placebo

  • Experimental
    Jaktinib 400mg

    6 Participants will receive Jaktinib 400 mg, orally; 2 Participants will receive placebo, orally.

    Drug: Jaktinib · Drug: Placebo

  • Experimental
    Jaktinib 600mg

    6 Participants will receive Jaktinib 600 mg, orally; 2 Participants will receive placebo, orally.

    Drug: Jaktinib · Drug: Placebo

  • Experimental
    Jaktinib 800mg

    6 Participants will receive Jaktinib 800 mg, orally; 2 Participants will receive placebo, orally.

    Drug: Jaktinib · Drug: Placebo

Interventions

  • Participants will receive Jaktinib orally for single dose

  • DrugPlacebo

    Participants will receive Placebo orally for single dose

06

What researchers measure

Primary outcomes

  1. QT Interval Corrected Using Fridericia's Formula

    Model-guided placebo-corrected change in QTcF from baseline (ΔΔQTcF)

    Time frame: From before dosing until 48 hours after dosing

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhu, Jiangsu, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Jun 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2023
First posted
Jan 5, 2024
StartActual
Mar 19, 2024
Primary completionActual
Jun 18, 2024
CompletionActual
Jun 18, 2024
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06193148
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Mar 19, 2024
Primary completion
Jun 18, 2024
Completion
Jun 18, 2024
Last update
Dec 12, 2024

Study contacts

LiYan Miao
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion